partment of Beijing Tiantan Hospital between January 1985 and June 2012 were collected. This longitudinal cohort study was a prospective analysis of retrospectively collected data. The inclusion criteria were age < 18 years, a diagnosis of brainstem CM based on MRI, and parental consent to undergo followup. Exclusion criteria included 1 or more of the following items: no consent to followup, a history of treatment (surgery or radiotherapy) prior to referral to our hospital, or comorbidities (involving the brainstem, peripheral nerves, or other eloquent lobes) that impacted the precision of neurological function evaluation. All patients were registered and entered into the study. Informed consent was obtained from all study participants and their parents or caregiver. The Beijing Tiantan Hospital Research Ethics Committee approved the study.
Clinical and Demographic Data
At the initial clinical consultation for brainstem CM treatment, patient data were recorded and further stratified by lesion location (midbrain, pons, or medulla) for analysis (Table 1) ; these data included family history, birth information, prior hemorrhage episode and treatment, and comorbid neurological disease. Two neuroradiologists independently reviewed the images, and the diagnosis was established based on MRI findings that were evaluated using accepted criteria. 44, 50 Initial neuroradiographic characteristics, such as multiple CMs, size, location, perilesional edema, developmental venous anomaly (DVA), side, depth, and others, were reviewed extensively and determined according to previously reported methods (Table 2) . 35, 36 Lesion size was evaluated as the lesion equivalent diameter (abc) 1/3 , where a, b, and c represent the diameters as measured on axial, sagittal, and coronal MR images, respectively. The depth of the lesion was determined by the parenchyma located between the pial surface and the lesion on T1weighted imaging. In superficially seated lesions, the parenchyma between the pial surface and the lesion was lamellar, usually with a pial prominence; furthermore, the interlayer (thickness < 1 mm) appeared to be nearly absent or indistinguishable and the lesion was close to the pial surface or ependyma. In moderately seated lesions, the interlayer (thickness ranging from 1 to 2 mm) between the lesion and pial surface was visible but thin despite the presence or absence of a pial prominence. For deeply seated lesions, the thickness of the interlayer was usually more than 2 mm without an obvious prominence. An MRI followup evaluation was recommended at 3 and 6 months after diagnosis and then once every 2 years thereafter.
A definitive prospective hemorrhage was defined as an intra or extralesional hemorrhage as determined using MRI with an acute, new onset, or worsening focal neurological deficit referable to the anatomical location of the hemorrhage that occurred after the patient's initial presentation. 5, 6, 21, 36 Although patients may complain of headache, CMs have not been proven to cause chronic headache disorders in casecontrol studies. 5 A clinical event with medical records but without radiographic examination or for which the images were not available was defined as a probable prospective hemorrhage that was not included in the calculation of prospective annual hemorrhage rate. Radiography was recommended to be performed as soon as possible after the onset of clinical symptoms that were suspicious for hemorrhage. 5 Neurological functional status was assessed using the modified Rankin scale (mRS) score upon diagnosis and at the last followup. 3  2  0  1  1  39  3  32  4  2  17  4  9  4  3  11  2  5  4  4  12  3  7  2  5  3  1  0  2 
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Follow-Up
The inception of the study was the date of diagnosis in our institute, and the end point was the date of the most recent evaluation, death, surgery, or radiosurgery that was considered a censoring event. Followups were obtained prospectively and annually either in the clinic, via telephone, email, or written questionnaire. Followup MR images were reviewed and noted when available.
Statistical Analysis
Descriptive statistics (means, SDs, and percentages) were used for patient characteristics. The prospective annual hemorrhage rate was calculated as the number of hemorrhages divided by the cumulative followup durations. Univariate and multivariate Cox regression analyses were used to evaluate hemorrhage predictors and functional recovery risks, which were further illustrated using the KaplanMeier method. The hemorrhagefree survival analysis began at the date of the initial consultation and ended at the date of the earliest rehemorrhage or the date of censoring, whichever occurred first. The cumulative duration until complete recovery began at the most recent hemorrhage date and ended at the date of complete recovery (mRS score of 0) or the date of censoring, whichever occurred first. The analyses were performed using the SPSS statistical package (version 19.0, IBM), as well as a confidence interval (CI) online statistical tool (http:// vassarstats.net/prop1.html), with a significance level set at p < 0.05.
Results
Patient Demographics
Of the included 85 patients (69.4% male), the mean and median ages were 12.7 ± 4.0 and 13.0 years (range 10 months to 17.9 years), respectively (Table 1) . At presentation, 67 patients (78.8%) had a previous overt hemorrhage. Six patients (7.1%) were diagnosed with CMs incidentally due to either routine medical examination or brain trauma. A family history of CMs was documented in 2 patients (2.4%). One patient had a significant neurological comorbidity, a left frontal astrocytoma. Two patients (2.4%) had undergone surgery for the resection of lobar CMs, and 4 patients (4.7%) received a ventriculoperitoneal shunt without an attempt at resection of the CM.
The most common symptoms at diagnosis were cranial nerve deficits (n = 61, 71.8%) followed by motor deficits (n = 42, 49.4%), and neuropathic pain (n = 35, 41.2%); other neurological deficits are detailed in Table 3 . The mean initial mRS score was 2.0 ± 1.3 (range 0-5), and only 3 patients presented without symptoms (Table 1) .
Radiography
Multiple cerebral CMs and multiple brainstem CMs were found in 10 (11.8%) and 4 patients (4.7%), respectively. Each of the 4 patients harbored 2 brainstem CMs, the symptomatic lesions assumed to cause the neurological deficits that were included in the study, and another 4 minor lesions were excluded. The lesion distribution was midbrain (n = 15, 17.6%), pons (n = 53, 62.4%), and medulla (n = 17, 20.0%). The mean lesion size was 1.9 ± 0.7 cm (range 0.4-3.4 cm) ( and 18 (21.2%) patients, respectively. Hydrocephalus was observed in 8 patients (9.4%). Radiographic followup was available for review in 78 patients (91.8%). Four patients (4.7%) were lost to long term followup, with an available mean followup duration of 3.3 years. Overall, 56 patients (65.9%) received treatment as a censoring event, including resection (n = 51), Gamma Knife surgery (n = 4), and CyberKnife treatment (n = 1). In our institute, we did not recommend radiotherapy to patients with brainstem CMs because of the undefined therapeutic effectiveness of radiotherapy on brainstem CMs and the inherent complications of radiation damage to the brainstem and possible pathogenesis for de novo CMs. However, Gamma Knife and CyberKnife surgeries in the 5 patients were performed at other hospitals primarily due to multiple hemorrhages (n = 3) and neurological deficits (n = 2). Reasons for recommending surgical treatment to the 51 patients included 1 or more of the following items: lesion sizes ≥ 2 cm, multiple hemorrhages, severe or progressive neurological dysfunctions, significant mass effect, exophytic lesions, or lesions abutting the pial membrane, which is accessible via safe entry zones. Overall, patient management was individualized.
Prospective Hemorrhage
During a mean followup of 4.7 ± 6.7 years (range 0.1-29 years), 47 hemorrhages occurred in 37 patients (43.5%), of which 10 (21.3%), 21 (44.7%), and 30 (63.8%) hemorrhages occurred within 6, 24, and 60 months, respectively. Six patients (7.1%) had multiple hemorrhages (4 patients had 2 hemorrhages and 2 had 4 hemorrhages). The mean interval between the first prospective hemorrhage and diagnosis was 45. (Table 4) . A multivariate analysis indicated that a lesion size ≥ 2 cm (HR 2.122, 95% CI 1.047-4.300; p = 0.037) and the presence of perilesional edema (HR 2.192, 95% CI 1.041-4.618; p = 0.039) remained statistically significantly associated with prospective hemorrhage.
During the total cumulative followup duration of 401.6 patientyears, the calculated prospective hemorrhage rate was 11.7% per patientyear. The highest hemorrhage rate was identified within the first 6 months (Table  5) , and the hemorrhage risk declined over time and significantly after the first 2 years. Higher annual hemorrhage rate-related adverse predictors included a lesion size ≥ 2 cm (OR 2.492, 95% CI 1.333-4.659, p = 0.003) and the presence of perilesional edema (OR 2.804, 95% CI 1.409-5.578, p = 0.002); lesions in the pons predicted significantly higher annual hemorrhage rate than lesions in the medulla (OR 2.890, 95% CI 1.154-7.236, p = 0.019; Table 6 ). Patients 12 years old or older exhibited a trend toward higher annual hemorrhage rates compared with patients younger than 12 years old, although this statistic was not significant (p = 0.056). A trend of hemorrhage risk declining with the passage of time was also observed when the annual hemorrhage rate was categorized by perilesional edema, lesion size, or lesion location (Table 5) . Overall, the prospective hemorrhagefree survival at 3 and 6 months and at 1, 2, 5, 10, and 15 years was 90.6%, 85.7%, 71.5%, 65.1%, 49.4%, 27.5%, and 13.7%, respectively (Fig. 1C) .
Functional Outcomes
At the most recent evaluation, the mean mRS score was 1.5 ± 1.4, which was significantly better than that at the initial diagnosis (1.5 < 2.0, t = 2.312, p = 0.023; Table  7 ). Compared with the initial mRS score, the recent mRS score improved in 33 patients (38.8%), stabilized in 32 patients (37.6%), and worsened in 20 (23.5%) without any deaths. Twentytwo patients (25.9%) obtained complete recovery, 41 patients (48.2%) lived independently with mild deficits, and 22 patients (25.9%) were dependent with moderate to severe disability. In 63 patients with various neurological dysfunctions of diverse severity, the most common deficits were motor and walking deficits in 15 patients, followed by sensory deficit and facial palsy; others are detailed in Table 3 .
A univariate analysis of the adverse predictors for cumulative percentage of complete recovery was limited Kaplan-Meier analysis illustrating hemorrhage risks (A and B) and hemorrhage-free survival (C). A lesion size ≥ 2 cm (A) and the presence of perilesional edema (B) were adverse predictors for future hemorrhage and had a shorter hemorrhagefree duration. The hemorrhage-free survival analysis (C) showed a rapid decline during the early period and a final poor outcome if given a sufficiently long follow-up duration. The hemorrhage-free survival rate at 15 years was only 13.7%.
to the first 5 years; although the followup was available after the first 5 years, complete recovery did not occur during that period. This analysis found that prospective hemorrhage was a significant risk factor for complete recovery (HR 0.196, 95% CI 0.065-0.589; p = 0.004; Table  8 , Fig. 2 left) . Patients with prior hemorrhage (p = 0.088) or a lesion ≥ 2 cm (p = 0.058) had a decreased chance of complete recovery, although these statistics were not significant (Table 8 ). After multivariate modeling was performed with adjustments for age and sex, prospective hemorrhage remained significant (HR 0.191, 95% CI 0.063-0.578; p = 0.003). The recent mRS score in patients with or without prospective hemorrhage was 2.0 ± 1.4 and 1.2 ± 1.3, respectively, and this difference was significant (2.0 > 1.2, t = -2.846, p = 0.006). Overall, the cumulative percentage of complete recovery at 3 and 6 months and at 1, 3, and 5 years was 23.2%, 32.7%, 40.8%, 43.6%, and 49.2%, respectively (Fig. 2 right) . These results indicated that complete recovery primarily developed within the first 12 months, which was considered an optimal time window for complete recovery.
Discussion
Pediatric brainstem CMs are rare and are estimated to account for 10.9%-14.5% of all brainstem CMs based on previous surgical series. 1, 2, 36, 48 Most previous studies included both adult and pediatric patients, were limited by their retrospective nature, or encountered inherent referral biases in surgical series that compromised the comparability between studies and obscured the natural history of pediatric brainstem CMs. Furthermore, studies differed in their hemorrhage definitions, the assumption of a congenital lesion, and neurological function evaluation methods. 1, 2, 4, 14, 24, 30, 35 In our study, we performed a prospective analysis of retrospectively collected data on the cohort of pediatric brainstem CMs with a stringent definition of hemorrhage and found that the annual hemorrhage rate was calculated to be 11.7% per patientyear, that both the presence of perilesional edema and a larger lesion size predicted poorer hemorrhagefree survival and a higher annual hemorrhage rate, and that prospective hemorrhage prevented complete neurological recovery (Fig. 2) . These results had an intrinsic dual character, and indicated the following: 1) only a few lesions (23.5%) behaved aggressively and led to further functional impairment; 2) hemorrhage risk declined over time (Table 5 ) and was parallel with the phenomena of the diminishing event rate and the temporal clustering of hemorrhage; 6, 8, 21 3) the cumulative percentage of complete recovery increased following the latest hemorrhage, but improvement and time did not appear to have a linear relationship; and 4) the chance of complete recovery decreased over time, especially after the first 12 months (Fig. 2) .
Hemorrhage Risk
In the largest surgical series of pediatric brainstem CMs, 1 the rehemorrhage rate was 44% per patientyear, which represented the subgroup of patients with a less benign clinical course that justified surgery. This high rehemorrhage rate was comparable with other surgical series that possessed inherent inclusion bias that could be amplified in the setting of a tertiary referral center. 21 reported a prospective annual hemorrhage rate of 2.25% in a cohort of 292 patients with cerebral CMs by retrospectively screening ini- tial radiographs for the identification of CM diagnosis. In a prospective populationbased cohort study by AlShahi et al., 6 the hemorrhage rate was calculated to be 0.5%, which increased to 2.1% if clinical events were included. In studies on the natural history of CMs (Table 9) , the documented subdivided annual hemorrhage rates for brainstem CMs differed greatly and were noted to be 2.33% if retrospective 13 annual hemorrhage rate of 2.46%, a clinical event rate of 3.4%, and a rehemorrhage rate of 5.1%. Another study by Tarnaris et al. 47 retrospectively cited a similar rehemorrhage rate of 5% in 21 cases of conservatively managed brainstem CMs. These diversities could be ascribed, as previously stated, to the limited number of patients, an insufficient followup duration, and the variance in individual study design. 4 Several risk factors for hemorrhage of CMs have been previously identified, including presentation with acute neurological symptoms 4, 6, 40 or hemorrhage, 21 CM size (≥10 mm), 30 and multiplicity of CMs. 4, 21 Furthermore, the overall annual hemorrhage rate was usually influenced by strict 40, 45 or lax 3,29,41 hemorrhage definitions, DVA, referral pattern, and familial lesions. 4, 15, 28, 32, 40, 50 Through comparing the included studies concerning the natural history of cerebral CMs (Table 9) 3,4,6,13,15,21,23,28-32,40,41,45,50 and based on the aforementioned risk factors, it was interesting to find that AlShahi et al., 6 Labauge et al., 31 and Robinson et al., 45 who reported the lowest rates (0.5%, 0.6%, and 0.7% per lesionyear, respectively), had the longest followup duration (8.8 years), the highest percentage of asymptomatic patients (100%), and the lowest percentage of patients presenting with hemorrhage (9.1%). It was also noteworthy that Moriarity et al., 40 with the highest hemorrhage rate per patientyear (3.1%) of the studies with a nonfamilial pattern of CMs, had the highest percentage of female patients (64.7%) and extremely few asymptomatic patients (1.5%). Additionally, the study of Kondziolka et al., 29 with a relatively high hemorrhage rate (2.6%), had the highest percentage of deeply located/infratentorial lesions (51.6%) and a notable number of patients with hemorrhage (50.0%). These phenomena could, in a way, explain the variable rates among prior studies. A detailed composition of the patient population should be taken into consideration when interpreting the hemorrhage rate.
Asymptomatic hemorrhage was occasionally detected in our series, and because of the feature of lowflow vascular lesions with cryptic biological behavior, the subclinical episode was likely to be overlooked and the hemorrhage rate was underestimated if patients did not receive scheduled radiographic reexaminations. The definition of asymptomatic hemorrhage was not consistent with the evidencebased consensus definition and reporting standards. 5 Hemorrhage rates between incidentally diagnosed patients and symptomatic patients were remarkably different, which would be inflated significantly in candidates for treatment intervention. 4, 21 Although lesion location did not impact hemorrhage rate, 3, 6, 21, 29, 40 hemorrhage from supratentorial lobar CMs may occasionally be occult or silent, and lesions in eloquent locations were likely to be more clinically aggressive. 41 Furthermore, Di Rocco et al. 16 confirmed that lesions in adults had a lower incidence of bleeding in their study, and younger children presented with significant hemorrhages more frequently than older children. Because patients were primarily referred by clinicians from local hospitals or by themselves in our series, this referral bias led to most patients having symptomatic hemorrhages. Given the above reasons, the char- acteristics in our series of young age with prior symptomatic hemorrhages in a majority of patients (78.8%), and the eloquent location of the brainstem sensitive to microhemorrhage, contributed to a relatively high hemorrhage rate. Additionally, the risk factors of perilesional edema and larger lesion size confirmed by our study further led to poor natural history, and the hemorrhage rate would be greatly elevated if more patients harbored these risks. Perilesional edema indicating a recent hemorrhage has not been verified as a risk factor for hemorrahge.
30 Edema could be a response to mass effect, inflammatory reaction, ischemia, venous outflow restriction, or the opening of preexisting arteriovenous connections, notwithstanding the angiographic occult feature proposed previously. 26 The presence of edema was not necessarily associated with lesion size, and we preferred the speculation of the probable invasiveness of the lesions and the infiltrated normal parenchyma. 35 The hemorrhage risk of a larger lesion size in our study was consistent with that of a prior study. 30 It could be inferred that despite the lowpressure lesions, the intralesional pressure would gradually increase along with the lesion size in the limited volume of the brainstem; if the pressure exceeded a critical point, the lesion could rupture, followed by significant clinical changes.
Although the hemorrhage interval was variable and unpredictable, a hemorrhage risk decline has been observed previously, and the latent period of rehemorrhage was extended. If a long period of observation elapsed and if the patients experienced relapsefree survival (including those with prior hemorrhages), 6, 8, 21 the utility of prior hemorrhages in predicting rehemorrhage may gradually weaken over time, thus the ostensible phenomenon of selfterminating hemorrhage. This decline provided some reassurance for patients when deciding on a treatment in clinical practice. Nonetheless, the precision of this apparent decline needs further investigation with an extended longitudinal follow up evaluation over the patients' lifetimes.
Functional Outcomes
The outcomes of untreated brainstem CMs vary in the literature (Table 10) . 10, 11, 14, 19, 22, 30, 34, 37, 38, 42, 47, 51 Among these studies, Tarnaris et al. 47 reported fairly poor outcomes, with 53.3% of patients exhibiting worsening conditions, and cited a neurological deterioration of 10% per patient year. An extremely malignant prognosis was reported with a mortality rate of 20%. 22 In contrast, acceptable outcomes were described in several series, stating that the natural history of brainstem CMs appeared to be more benign than previously believed. 14, 19, 30, 34 Overall, in 7 series that provided detailed outcomes, 11, 19, 30, 38, 42, 47, 51 88 (71.5%) of 123 patients were improved/unchanged, 33 patients (26.8%) worsened, and the mortality rate due to rehemorrhage was 4.1% (9/218). Another series consisting exclusively of 13 pediatric brainstem CMs revealed no change in function in 8 patients (61.5%) and improvement in 4 patients (30.8%).
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Our result was comparable to those in the literature; 65 patients (76.5%) were improved and 20 (23.5%) worsened, without any deaths. Additionally, a KaplanMeier analysis (Fig. 2) showed a higher full recovery percentage at 5 years (49.2%) than the actual result (38.8%), which suggested a trend of improvement over time. Unfortunately, we did not observe full recovery after the first 5 years, which paradoxically implied a time limit for the recovery. Therefore, we speculated that the optimal period for full recovery was limited to the first 12 months. We identified prospective hemorrhage as an adverse predictor for full recovery (Fig.  2) . A larger lesion size and prior hemorrhage predicted a poor outcome, although the statistical analysis for these variables did not reach significance (Table 8) .
Acute neurological decline resulting from the mass effect of hemorrhage would occasionally recover to initial functional status over time, except for brainstem parenchyma destroyed by hematoma rather than merely compressed by a spaceoccupying mass. Although complete recovery from the initial hemorrhage could be expected, it was obvious that repeated insults to the eloquent areas often resulted in severe and persistent deficits. 3 As with a previous interpretation, recurrent episodes acting as a second hit led to further neurological deterioration, decreased the functional baseline, and decreased the potential of full recovery. 35 After a longer period of time, if transient deficits did not show any improvement, they were more likely to be transformed into permanent, irreversible deficits.
Given the relatively smaller brain volume and larger lesion size compared with those in adults, pediatric patients suffered a more severe spaceoccupying effect and functional deterioration.
1 Conservative management should not be considered a benign therapy in all patients.
Moreover, longer life expectancy and better potential of functional restoration and compensation for the developing brain (compared with that of adults) encouraged parents and children to take a proactive attitude toward effective treatment in our series.
Based on the findings of this observational study and the experience of our institute, we recommended conservative management for pediatric patients who did not have severe neurological deterioration with only a single hemorrhage or had small (< 1 cm), deeply located, and inaccessible lesions. This observation period was preferred until patients suffered from a second hemorrhage that indicated the aggressiveness of the lesions and justified resection. A close followup was mandatory for conservatively managed patients and patients with hemorrhage risks if they declined surgery. Surgery was recommended for pediatric patients presenting with a large lesion size (≥ 2 cm) accompanied by significant mass effect, severe or progressive neurological dysfunction, or exophytic lesions or lesions abutting the pial membrane, which is accessible via safe entry zones, occasionally even if patients had only a single hemorrhage. A multiple hemorrhage event was an important surgical indication. Radiotherapy was not recommended in our institute. Additionally, when deciding on treatment strategy, the patients' goals and wishes should also be considered. On the whole, the management of pediatric brainstem CMs should be tailored to the individual patient in all cases.
Limitations of the Study
A referral pattern with inherent selection biases and insufficient followup duration were stressed in our study, which impacted the generalization and extrapolation to a patient population and greatly overestimated the hemorrhage rate compared with that of the general population. The data from the time of the initial symptoms to the presentation at our institute were not available, and we will attempt to minimize this limitation in future studies to improve our understanding of this disease. Because functional outcome was only analyzed in relation to prospective hemorrhage, we primarily focused on hemorrhage risk. A populationbased cohort study is recommended to investigate the natural history of brainstem CMs. Another 25 cases of pediatric brainstem CMs have entered into our study since June 2012, and we will continue the followup of conservatively managed patients to validate the precision of our findings.
Conclusions
The hemorrhage rate of pediatric brainstem CMs in our series was relatively high, which should be interpreted with caution based on the detailed analysis of the patient composition. The functional outcome was acceptable, and the hemorrhage risk declined over time, a finding that was useful for clinicians and patients when deciding on treatment. Risk factors predicting future hemorrhage and poor outcome require further investigation.
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